Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 13/20 | 0.73 |
| ▸ | ABL1 | P00519 | 12/20 | 0.73 |
| ▸ | BCR | P11274 | 6/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | PRKCA | P17252 | 1/20 | 0.73 |
| ▸ | KIT | P10721 | 7/20 | 0.67 |
| ▸ | KDR | P35968 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099865 | 0.90 | ABL1 (0.77) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL1408815 | 0.89 | ABL1 (0.77) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL1415439 | 0.86 | ABL1 (0.74) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL2004455 | 0.85 | PDGFRA (0.91) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL869136 | 0.85 | ABL1 (0.72) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL29441265 | 0.85 | ABL1 (0.77) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL868006 | 0.85 | ABL1 (0.77) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL1449866 | 0.85 | ABL1 (0.82) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL1448495 | 0.85 | ABL1 (0.70) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL29498750 | 0.85 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102046617-B | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD | 2014-08-20 | — | — | CN | disclosed |
| CN-102046617-B | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD | 2014-08-20 | — | — | CN | disclosed |
| EP-2426119-B1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD (IN) | 2013-10-09 | — | — | EP | disclosed |
| EP-2426119-B1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD (IN) | 2013-10-09 | — | — | EP | disclosed |
| EP-2426119-B1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD (IN) | 2013-10-09 | — | — | EP | disclosed |
| EP-2254882-B1 | USE OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL -3-(4-PYRIDIN-3-YL-PYRIMIDIN-2YL-AMINO)-PHENYL]-BENZAMIDE AGAINST BREAST CANCER, GLIOMA AND ANGIOGENESIS. | NATCO PHARMA LTD (IN) | 2012-07-18 | — | — | EP | disclosed |
| EP-2254882-B1 | USE OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL -3-(4-PYRIDIN-3-YL-PYRIMIDIN-2YL-AMINO)-PHENYL]-BENZAMIDE AGAINST BREAST CANCER, GLIOMA AND ANGIOGENESIS. | NATCO PHARMA LTD (IN) | 2012-07-18 | — | — | EP | disclosed |
| EP-2254882-B1 | USE OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL -3-(4-PYRIDIN-3-YL-PYRIMIDIN-2YL-AMINO)-PHENYL]-BENZAMIDE AGAINST BREAST CANCER, GLIOMA AND ANGIOGENESIS. | NATCO PHARMA LTD (IN) | 2012-07-18 | — | — | EP | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| WO-2009109866-A2 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3- (4-PYRIDIN-3-YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109866-A2 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3- (4-PYRIDIN-3-YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | disclosed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | disclosed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | disclosed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | disclosed |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LIMITED (IN) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | ABL1, ABL2, BCR | PDGFRA 9/4885ABL1 1/4885BCR 3/4885 |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | PDGFRA 113/4885ABL1 1/4885BCR 3/4885 |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | AZI2, NNMT, ALKBH2 | PDGFRA 266/4885ABL1 58/4885BCR 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.